Detection of fucosylated ITGA3 in the ITGA3-UEA assay (anti-ITGA3 antibody and fucose-specific Ulex europaeus agglutinin (UEA lectin) conjugated on nanoparticles) has shown that this recognized glycovariant significantly discriminate BC patients from benign hyperplasia patients [164]. This evidence concerns the gene ITGA3 and breast cancer.